Scientific Program - Friday 10 May

Print
 
Friday 10 May, 2019   Saturday 11 May, 2019
 
Friday 12 April, 2019
HALL A
08:30-09:15 
08:30-09:00
09:00-09:15
Plenary | Key Note Lecture
Diabetes prevention and early treatment
Discussion
HALL A
09:15-10:45

09:15-09:20
09:20-09:30
09:30-09:40
09:40-09:45
09:45-10:00

10:00-10:05
10:05-10:15
10:15-10:25
10:25-10:30
10:30-10:45
Session 1 – Diabetes
Should glucosidase inhibitors be the first drug in type 2 diabetic patients in Asia?
Case Presentation
Yes
No
Case Presentation
Discussion
Prevention of cardiac events in primary prevention: Should we use SGLT2 or glucosidase inhibitors?
Case Presentation
SGLT2
Glucosidase inhibitors
Case Presentation
Discussion
HALL B
09:15-10:45

09:15-09:20
09:20-09:30
09:30-09:40
09:40-09:45
09:45-10:00

10:00-10:05
10:05-10:15
10:15-10:25
10:25-10:30
10:30-10:45
Session 2 – Hypertension and Diabetes
Is the CVO in CVOT’s applicable for the Asian population?
Case Presentation
Yes
No
Case Presentation
Discussion
Should SGLT2i be considered drugs for cardiologists/nephrologist/family physician?
Case Presentation
Yes
No
Case Presentation
Discussion
10:45-11:15
VISIT EXHIBITS & COFFEE BREAK
HALL A
11:15-12:45

11:15-11:20
11:20-11:30
11:30-11:40
11:45-11:45
11:45-12:00

12:00-12:05
12:05-12:15
12:15-12:25
12:25-12:30
12:30-12:45
Session 3 – Diabetes
Should we treat NASH by drugs or surgery?
Case Presentation
Yes
No
Case Presentation
Discussion
Are biosimilar insulins equal to originators?
Case Presenatation
Yes
No
Case Presentation
Discussion
HALL B
11:15-12:45

11:15-11:20
11:20-11:30
11:30-11:40
11:45-11:45
11:45-12:00

12:00-12:05
12:05-12:15
12:15-12:25
12:25-12:30
12:30-12:45
Session 4 – Nephropathy
Can nephropathy be reversed?
Case Presentation
Yes
No
Case Presentation
Discussion
How early should SGLT2 be given to the diabetic patient?
Case Presentation
Very early
Relatively late
Case Presenation
Discussion
12:45-13:15
VISIT EXHIBITS & LUNCH
HALL A
13:15-14:15
INDUSTRY-SPONSORED SYMPOSIUM
HALL B
13:15-14:15
INDUSTRY-SPONSORED SYMPOSIUM
HALL A
14:15-15:45

14:15-14:20
14:20-14:30
14:30-14:40
14:40-14:45
14:45-15:00

15:00-15:05
15:05-15:15
15:15-15:25
15:25-15:30
15:30-15:45
Session 5 – Diabetes
Is SGLT2 a safe drug?
Case Presentation
Yes
No
Case Presentation
Discussion
Cancer morbidity and Mortality: Should metformin be given to every diabetic person?
Case Presentation
Asia
Rest of the World
Case Presentation
Discussion
HALL B
14:15-15:45

14:15-14:20
14:20-14:30
14:30-14:40
14:40-14:45
14:45-15:00

15:00-15:05
15:05-15:15
15:15-15:25
15:25-15:30
15:30-15:45
Session 6 – Hypertension
Should we constantly monitor 24 B/P in patients with hypertension?
Case Presentation
Asia
Rest of the World
Case Presentation
Discussion
Volume overload is the main mechanism of resistant hypertension?
Case Presentation
Yes
No
Case Presentation
Discussion
15:45-16:00
VISIT EXHIBITS & COFFEE BREAK
HALL A
16:00-17:30

16:00-16:05
16:05-16:15
16:15-16:25
16:25-16:30
16:30-16:45

16:45-16:50
16:50-17:00
17:00-17:10
17:10-17:15
17:15-17:30
Session 7 – Diabetes
Should we change the A1C target in newly diagnosed patients?
Case Presentation
Asia
Rest of the World
Case Presentation
Discussion
Glucosidase inhibitors or metformin as a first line of therapy?
Case Presentation
Glucosidase inhibitors
Metformin
Case Presentation
Discussion
HALL B
16:00-17:30

16:00-16:05
16:05-16:15
16:15-16:25
16:25-16:30
16:30-16:45

16:45-16:50
16:50-17:00
17:00-17:10
17:10-17:15
17:15-17:30
Session 8 – Obesity
Does non bariatric reduction in weight improve CVO in T2D patients?
Case Presentation
Asia
Rest of the World
Case Presentation
Discussion
Should we reduce weight in elderly T2D patients?
Case Presentation
Asia
Rest of the World
Case Presentation
Discussion